Evidence map›Paper›PMID 39369573›Full record

ArticleThe International journal on drug policy2024

The intersection of substance use stigma and anti-Black racial stigma: A scoping review.

Rashmi Ghonasgi, Maria E Paschke, Rachel P Winograd, Catherine Wright, Eva Selph, Devin E Banks

Abstract readScoping Review
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rashmi GhonasgiDepartment of Psychological Sciences, University of Missouri-St. Louis, St. Louis, MO, United States.
Maria E PaschkeDepartment of Psychological Sciences, University of Missouri-St. Louis, St. Louis, MO, United States; Missouri Institute of Mental Health, University of Missouri-St. Louis, St. Louis, MO, United States.
Rachel P WinogradDepartment of Psychological Sciences, University of Missouri-St. Louis, St. Louis, MO, United States; Missouri Institute of Mental Health, University of Missouri-St. Louis, St. Louis, MO, United States.
Catherine WrightCollege of Education, University of Missouri-St. Louis, St. Louis, MO, United States.
Eva SelphDepartment of Psychological Sciences, University of Missouri-St. Louis, St. Louis, MO, United States.
Devin E BanksDepartment of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, MO, United States. Electronic address: banks.devin@wustl.edu.

Funding

An Integrated Geospatial and Community-based Model to Prevent Opioid Overdose among Black AmericansK08DA058080 · NIDA · WASHINGTON UNIVERSITY · PI Devin Banks · 2023 to 2026
$774k
NIDA NIH HHS K08 DA058080
6 · The paper itself

Abstract

backgroundSubstance use stigma poses a barrier to treatment and recovery from substance use disorder. Stigma is amplified when intersecting with other stigmatized identities, particularly Black racial identity. Despite increasing attention to the intersecting roles of racial and substance use stigma, it is unknown how these stigmas interact to impact treatment and health outcomes among Black people who use drugs. This scoping review examines empirical research documenting differential impacts of race and racism on substance use stigma.

methodsWe systematically searched PsychInfo and PubMed databases. Eligible studies were conducted in the U.S.; examined a Black sample, subsample, or experimental condition/variable (i.e., in a vignette); and measured substance use stigma (excluding alcohol or nicotine). Qualitative studies describing a theme related to substance use stigma were also included.

resultsOf 1431 unique results, 22 articles met inclusion criteria. The most measured substance use stigma type was interpersonal (e.g., discrimination). Most quantitative findings (n = 15) suggested that Black members of the general public endorse less substance use stigma and Black people who use drugs face less substance use stigma relative to their White counterparts. Qualitative studies (n = 7) suggested stigma was a more common and pernicious substance use treatment barrier for Black people compared to White. Across methods, racial prejudice was associated with substance use stigma, supporting hegemonic ideas that substance use is stereotypically characteristic of Black people.

conclusionsThe interaction between substance use stigma and race is complex and varies by in-group and out-group raters as a function of racial identity and identity as a person who uses drugs. Contradictory findings reflect methodological differences, emphasizing the need for more unified measurement of substance use stigma. More research is needed among Black people who use drugs to improve understanding of the impact of these intersecting stigmas on racial inequities in substance use treatment, morbidity, and mortality.

Indexed as

Black or African AmericanRacismSocial StigmaSubstance-Related DisordersHumansStereotypingUnited StatesBlackPeople who use drugsRacial inequitiesRacismStigmaSubstance use

Identifiers

PMID39369573
PMCPMC11571710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.